Sign In

Friday, February 01, 2019 - 8:00 am to Saturday, February 02, 2019 - 12:15 pm
Add to Calendar

Abstract submission closed Monday, December 10, 2018.

Course Description / Needs Statement

The goal of the conference is to promote global elimination of hepatitis C infection. World leaders in the related disciplines will assemble to establish the current state of the science and public health challenges. The experts will then formulate the most effective future steps toward elimination.

Program Chairs

  • Raymond T. Chung, MD, FAASLD
  • David L. Thomas, MD
  • Markus Cornberg, MD
  • Alessio M. Aghemo, MD, PhD

Location

  • Hyatt Regency Miami
    400 SE Second Avenue
    Miami, FL 33131-2197
    Phone: 305-679-3048

Learning Objectives

  • Describe the major obstacles to global elimination of HCV infection
  • Identify measures that are likely to reduce the burden of disease
  • Compare the historic successes to the future needs

Core Competencies

  • Medical Knowledge
  • Work in Interdisciplinary Teams
  • Apply Quality Improvement
  • Values/Ethics for Interpersonal Practice
  • Roles / Responsibilities
  • Teams and Teamwork

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7 am ET both days.

Registration Pricing Early Bird: On or Before January 2

  • Member $325
  • Trainee & Assoc. Members $185
  • Non-Member $540
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $235
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $775
    Any Industry (pharma/device/etc.) employee with or without medical training.

Registration Pricing: On or after January 3

  • Member $425
  • Trainee & Assoc. Members $210
  • Non-Member $640
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $260
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $875
    Any Industry (pharma/device/etc.) employee with or without medical training.

Registration Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

Cancellations received on or before January 1, 2019 will be eligible for a full refund.

Cancellations received between January 2 and January 16 will be subject to a $50.00 cancellation fee.

Cancellations received between January 17 and February 18 are not eligible for a refund.

Friday, February 1 -- Session I

Session I: From Discovery to Elimination
Moderators: Michael P. Manns, MD and Harvey Alter, MD, FAASLD

  • 8:00 am – 8:30 am
    HCV: From Hippocrates to Cure
    Harvey Alter, MD, FAASLD
  • 8:30 am – 9:00 am
    Worldwide HCV Epidemiology and Impact of Treatment
    John W. Ward, MD (CDC)
  • 9:00 am – 9:30 am
    Models for HCV Epidemics: What should we expect?
    Andrew M. Hill, PhD
  • 9:30 am – 10:00 am
    Break

Friday, February 1 -- Session II

Session II: Prevention of HCV infection
Moderators: Norah Terrault, MD, MPH, FAASLD and David L. Thomas, MD

  • 10:00 am – 10:20 am
    Immunologic Attributes of an Effective Vaccine
    Eleanor J. Barnes, BSc, PhD, MRCP
  • 10:20 am – 10:40 am
    HCV Vaccine: Data from Clinical Trials
    Andrea Cox, MD, PhD
  • 10:40 am – 11:00 am
    Harm Reduction Measures: What Works
    Natasha Martin, MD
  • 11:00 am – 11:20 am
    Treatment of Early / Acute HCV Infection: Treatment as Prevention?
    Michael P. Manns, MD
  • 11:20 am – 11:50 am
    Roundtable: What Do We Need to Prevent HCV Infection?
  • 11:50 am – 1:00 pm
    Lunch

Friday, February 1 -- Session III

Session III: Implementation of Cure
Moderators: Jean-Michel Pawlotsky, MD, PhD, FAASLD and John W. Ward, MD

  • 1:00 pm – 1:20 pm
    Clinical Challenges in Treating HCV
    Alessio Aghemo, MD, PhD
  • 1:20 pm – 1:40 pm
    Patient Characterization at Baseline: What is Essential?
    Norah Terrault, MD, MPH, FAASLD
  • 1:40 pm – 2:00 pm
    Treating High-risk Groups: How to Manage?
    Sally Hodder, MD
  • 2:00 pm – 2:30 pm
    Roundtable: Can We Still Optimize Treatment to Cure All?
  • 2:30 pm – 3:00 pm
    Break

Friday, February 1 -- Session IV

Session IV: Implications of Cure – Clinical and Translational
Moderators: Eleanor J. Barnes, BSc, PhD, MRCP and Alessio Aghemo, MD, PhD

  • 3:00 pm – 3:20 pm
    Clinical Impact of HCV Cure on Liver Disease and HCC
    Hashem B. El-Serag, MD, MPH
  • 3:20 pm – 3:40 pm
    Clinical Impact of Cure on Extrahepatic Manifestations
    Raymond T. Chung, MD, FAASLD
  • 3:40 pm – 4:00 pm
    Biological Impact of HCV Cure
    Markus Cornberg, MD
  • 4:00 pm – 4:30 pm
    Roundtable: Is HCV Cure Really a Cure of Everything? - Is There a Point of No Return?
  • 4:30 pm – 5:00 pm
    Breaking news (2 featured abstracts)
  • 5:00 pm – 6:00 pm
    Poster Reception

Saturday, February 2 -- Session V

Session V: Models of Cure
Moderators: Harvey Alter, MD, FAASLD and Homie Razavi, PhD

  • 8:00 am – 8:20 am
    America (VA)
    Lisa I. Backus, MD, PhD
  • 8:20 am – 8:40 am
    Asia (Australia)
    Alexander J.V. Thompson, MD, PhD
  • 8:40 am – 9:00 am
    Africa (Egypt)
    Imam Waked, MD, FRCP, FAASLD
  • 9:00 am – 9:20 am
    Europe (including Georgia)
    Francesco Negro, MD
  • 9:20 am – 9:50 am
    Q&A and Panel Discussion
  • 9:50 am – 10:20 am
    Break

Saturday, February 2 -- Session VI

Session VI: Looking to the Future: Elimination of HCV Based on Past and Current Experiences
Moderators: Markus Cornberg, MD and Raymond T. Chung, MD, FAASLD

  • 10:20 am – 10:40 am
    The Cost of Elimination
    Jag Chhatwal, PhD
  • 10:40 am – 11:00 am
    Use of HCV Organs in Transplantation
    Marina Berenguer, MD
  • 11:00 am – 11:20 am
    Is there a Risk for Multiresistant HCV?
    Jean-Michel Pawlotsky, MD, PhD, FAASLD
  • 11:20 am – 11:50 am
    Roundtable: What Are the Remaining Challenges? (including Michael P. Manns, MD and David L. Thomas, MD)
  • 11:50 am – 12:15 pm
    A Closing Poem
    Harvey Alter, MD, FAASLD
  • 12:15 pm
    Adjourn